Want to see GB:DXRX full AI Analyst Report?

Diaceutics (DXRX) Earnings Dates, Call Summary & Reports

Q: When does Diaceutics (GB:DXRX) report earnings?

Diaceutics (GB:DXRX) is schdueled to report earning on Sep 29, 2026, Before Open (Confirmed).

Q: What is Diaceutics (GB:DXRX) earnings time?

Diaceutics (GB:DXRX) earnings time is at Sep 29, 2026, Before Open (Confirmed).

Q: Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

Q: What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

Q: What is the P/E ratio of Diaceutics stock?

The P/E ratio of {name} is N/A.

Q: What is GB:DXRX EPS forecast?

GB:DXRX EPS forecast for the fiscal quarter 2026 (Q2) is -0.03.

11 Followers

Earnings Data

Report Date

Sep 29, 2026

Before Open (Confirmed)

Period Ending

2026 (Q2)

Consensus EPS Forecast

-0.03

Last Year’s EPS

-0.03

Same Quarter Last Year

Analyst Consensus

Moderate Buy

Based on 1 Analysts Ratings

Earnings Call Summary

Q2 2024

Earnings Call Date:Sep 17, 2024|

% Change Since:

Earnings Call Sentiment|Positive

The earnings call presented a mix of positive developments, particularly with revenue growth, high gross margins, and the strategic launch of the PMx solution, alongside record order book figures. However, challenges such as the increased EBITDA loss and decreased TCV were noted. The overall sentiment leans towards optimism, driven by strategic advancements and strong financial positioning.

Company Guidance

In the Q2 2024 earnings call for Diaceutics, CEO Ryan Keeling detailed significant advancements achieved in the first half of the year, particularly emphasizing the launch of their PMx solution. The company has expanded its lab network, notably integrating rare disease data and enhancing European data capabilities, all contributing to a robust and automated data pipeline. This automation, aided by AI, has streamlined data handling from extraction to customer delivery. The PMx solution, which emerged as a pivotal development, has transformed their approach by directly engaging physicians with patient data, boosting engagement and conversion rates. The financial health of the company is strong, with a 24% revenue increase to £12.3 million and a gross profit margin of 87%. Diaceutics aims to transition to a 70% subscription-led revenue model by 2025, with recurring revenues currently at 55%. The company also reported a record order book of £27.9 million, with plans to achieve profitability and free cash flow generation by 2025.

Revenue Growth

Revenue increased to GBP 12.3 million, up 24% or 28% on a constant currency basis, with 55% of revenue now being subscription-based.

High Gross Margin

Gross profit margins in H1 were 87%, with expectations to maintain around 85% for the full year.

PMx Launch

Launched the PMx solution which integrates the last 2 years of investment, offering a GBP 2 million per year per brand revenue potential, with higher levels of conversion and patient engagement.

Enterprise-wide Engagements

Increased the number of enterprise-wide engagements from 4 to 7 since FY '23, representing a key area of growth.

Strong Balance Sheet

Cash reserves of GBP 16.7 million with no debt, projecting a low point of GBP 13 million by year-end.

Record Order Book

Order book at a record high of GBP 27.9 million, providing 71% visibility of full-year consensus analyst guidance revenue.

Diaceutics (GB:DXRX) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

GB:DXRX Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Sep 29, 2026	2026 (Q2)	-0.03 / -	-0.028	―	―	―
May 26, 2026	2025 (Q4)	0.03 / 0.03	0.01	200.00% (+0.02)
Sep 23, 2025	2025 (Q2)	-0.03 / -0.03	-0.031	9.68% (<+0.01)		―
May 13, 2025	2024 (Q4)	0.02 / 0.01	-0.003	433.33% (+0.01)
Sep 17, 2024	2024 (Q2)	-0.04 / -0.03	-0.018	-72.22% (-0.01)
May 21, 2024	2023 (Q4)	<0.01 / >-0.01	0.018	-116.67% (-0.02)
Sep 26, 2023	2023 (Q2)	- / -0.02	-0.009	-100.00% (>-0.01)
Apr 17, 2023	2022 (Q4)	0.01 / 0.02	0.011	63.64% (<+0.01)	―
Sep 27, 2022	2022 (Q2)	- / >-0.01	-0.004	-125.00% (>-0.01)	―	―
Mar 22, 2022	2021 (Q4)	<0.01 / 0.01	-0.01	210.00% (+0.02)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

GB:DXRX Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
May 26, 2026	166.50 p	151.00 p	-9.31%
Sep 23, 2025	152.00 p	159.00 p	+4.61%
May 13, 2025	125.00 p	135.00 p	+8.00%
Sep 17, 2024	127.50 p	132.50 p	+3.92%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Diaceutics (GB:DXRX) report earnings?

Diaceutics (GB:DXRX) is schdueled to report earning on Sep 29, 2026, Before Open (Confirmed).

What is Diaceutics (GB:DXRX) earnings time?

Diaceutics (GB:DXRX) earnings time is at Sep 29, 2026, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is the P/E ratio of Diaceutics stock?

The P/E ratio of Diaceutics is N/A.

What is GB:DXRX EPS forecast?

GB:DXRX EPS forecast for the fiscal quarter 2026 (Q2) is -0.03.